Xiao Fang Pharma entrusts BOJI CRO to develop traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture" (indication for hair loss)
Xiao Fang Pharma and BOJI CRO signed a technical entrustment contract, in which BOJI CRO will assist in completing the clinical research and registration of the traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture." This cooperation marks an important progress for Xiao Fang Pharma in the field of innovative drugs, as both parties will leverage their respective advantages to enhance R&D efficiency and lay the foundation for product launch
According to the Zhitong Finance APP, Xiao Fang Pharma (603207.SH) announced that the company recently signed a "Technical Entrustment (Development) Contract" with BOJI CRO. BOJI CRO will assist the company in completing the clinical research and registration of the new drug compound Cèbǎi Dīng (Class 1.1 Traditional Chinese Medicine), promoting the completion of clinical trials and market launch.
The "Technical Entrustment (Development) Contract" signed between the company and BOJI CRO represents a strong alliance based on a common development strategy, marking an important step in the company's layout in the innovative drug field. As an industry-leading enterprise, BOJI CRO has significant advantages in research and development capabilities, technical accumulation, and clinical resources. The cooperation between the two parties will fully leverage their respective strengths, create a synergistic effect, effectively enhance the research and development efficiency and success rate of the contracted product, and lay a solid foundation for the subsequent application and market launch of the product
